NEW YORK, May 2 – Paradigm Genetics’ gene function discovery partnerships with Monsanto and Bayer began to pay off as its first quarter revenues surged to $5.5 million, compared to $593,000 for the first quarter of 2000, the company said Wednesday.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.
Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.
Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.
Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.